The Mark Foundation for Cancer Research shared on X:
“We’ve had two thrilling days in Dallas gathering the scientific community for Advancing Immunotherapy for Osteosarcoma, organized with The Osteosarcoma Institute. The challenges are immense, but so is the potential.
Together, we’re working toward better treatments for patients who urgently need them.”
You can also read:
Collagen-Targeted IL-12 Plus Doxorubicin in Osteosarcoma
